Travere Therapeutics' Deferred Taxes rose 111.88% to $1.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$6.4 million, marking a year-over-year increase of 71.65%. This contributed to the annual value of -$6.4 million for FY2017, which is 71.65% up from last year.
Per Travere Therapeutics' latest filing, its Deferred Taxes stood at $1.4 million for Q4 2017, which was up 157.97% from -$2.4 million recorded in Q3 2017.
In the past 5 years, Travere Therapeutics' Deferred Taxes ranged from a high of $28.2 million in Q3 2015 and a low of -$40.0 million during Q1 2015.
Over the past 3 years, Travere Therapeutics' median Deferred Taxes value was -$3.4 million (recorded in 2017), while the average stood at -$4.1 million.
Data for Travere Therapeutics' Deferred Taxes shows a peak YoY increase of 111.88% (in 2017) and a maximum YoY decrease of 285.78% (in 2017) over the last 5 years.
Over the past 4 years, Travere Therapeutics' Deferred Taxes (Quarterly) stood at -$2.5 million in 2014, then slumped by 53.74% to -$3.8 million in 2015, then tumbled by 208.36% to -$11.7 million in 2016, then skyrocketed by 111.88% to $1.4 million in 2017.
Its Deferred Taxes was $1.4 million in Q4 2017, compared to -$2.4 million in Q3 2017 and -$3.4 million in Q2 2017.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value